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Critical Evaluation of Simazine’s Breast Cancer Risk
Authors’ Note:  The reader is encouraged to read Appendix B prior to reading this Critical Evaluation.  Appendix B includes an explanation
of the approach used in writing BCERF Critical Evaluations and an explanation of the BCERF Breast Cancer Risk Classification System.
Chimiche Caffaro S.p.A.); Simazat®, simazine + atrazine (Drexel
Chem. Co.); Simazol®, simazine + amitrole (Makhteshim-Agan);
Terbutrex Combi®, simazine + terbutryn (Makhteshim-Agan);
Terraklene®, simazine + paraquat (Sopra); Topanex®, simazine
+ diuron + glycophosate (Aragonesas Agro); Trevi 10® simazine
+ diuron (Calliope S.A.); Tropazin®, simazine + glyphosate
(Herbitecnica Industria de Defensivos) (Meister, 1998)
*Note:  Trade names are used herein for convenience and
informational purposes only.  No endorsement of products is
intended and no criticism of unnamed products is implied.  Trade
names of simazine and mixtures containing simazine listed here
are those currently in use in 1998.
H. Major Transformation Products:
Simazine can be photodegraded to produce low levels of the mono-
N-deethylated metabolite (2-chloro-4-[ethylamino]-6-amino-s-
triazine); the di-N-deethylated metabolite (2-chloro-4,6-
bis[amino]-s-triazine); and hydroxy simazine (2-hydroxy-4,6-
bis[ethylamino]-s-triazine).  Photodegredation is considered to be
a minor route of degredation of simazine in surface soils (WSSA,
1994).
Hydrolysis of simazine can occur in the roots of tolerant plants to
produce hydroxy simazine.  This occurs through a benzoxazinone-
catalyzed hydrolysis (WSSA, 1994; Kearney and Kaufman, 1969).
Hydrolysis of simazine has also been reported under controlled
conditions in soil treated with simazine (Harris, 1967).  The N-
dealkylation of side chains can also occur in some plants.  In some
tolerant plants, including corn, a transformation route includes
conjugation of simazine with glutathione (chemical structure/for-
mula not specified) (WSSA, 1994). The major metabolite of
simazine by aerobic microbial degradation in soil is hydroxy
simazine (WSSA, 1994).  Under anaerobic conditions,
transformation products in soil have included dealkylated forms
of simazine, 2-chloro-4-(ethylamino)-6-amino-s-triazine and 2-
chloro-4,6-bis(amino)-s-triazine; and dechlorinated hydroxylated
products, 2-hydroxy-4,6-bis(ethylamino)-s-triazine, and 2-
hydroxy-4-ethylamino-6-amino-s-triazine (IARC, 1991).
In vitro studies, using 14C radiolabled simazine and hepatic
microsomes isolated from mice and rats, have shown that simazine
is metabolized by cytochrome P-450 enzymes primarily via N-
dealkylation by the loss of the ethyl group to form 2-chloro-4-
I. Chemical Information
A. Common Name:  Simazine (Meister, 1998)
B. Chemical Name:  6-chloro-N,N’-diethyl-1,3,5-triazine-2,4-
diamine (Meister, 1998)
C. Chemical Formula:  C7H12ClN5 (Montgomery, 1993)
D. CAS Registry Number:  122-34-9 (Meister, 1998)
E. Chemical Structure: (WSSA, 1994)
Simazine
F. Trade Names*:   Trade names include: Agrisimazina®
(Cequisa); Caliber® 90 (Norvartis); Drexel® Simazine (Drexel
Chemical Co.); Gesatop® (Norvartis); Herbanzin® (Herbitecnica
Industria de Defensivos S/A); Princep® (Norvartis); Sanazine®
(Sanachem Ltd.); Sarvave® (Lainco, S.A.); Simanex®
(Makhteshim-Agan); Simapron-50® (Probelte, S.A.);
Simatylone® (Chimac-Agriphar S.A.); Simazin® (Sintagro Ltd.);
Simazina Atanor® (Atanor S. A.); Simatylone® (Chimac-Agriphar
S.A.); Simin® (Industrie Chimiche Caffaro S.p.A.); Sim-Trol®
(Sostram Corp.); and Totazina® (Diachem S.p.A.) (Meister, 1998).
G. Trade Names of Mixtures*:  Derby®, simazine + metolachlor
(Norvartis); Duacit®, simazine + terbutryn (Luxan B.V.);
Herbimix®, simazine + atrazine (Herbitecnica Industria de
Defensivos); Linusim SA®, simazine + linuron (Sintagro Ltd.);
Pathclear®, simazine + diquate + paraquat (ZENECA
Agrochemicals); Sartax®, simazine + diuron + metazachlor (CFPI
Agro); Simatrol® 55, simazine + atrazine + amitrole (Industrie
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(ethylamino)-6-amino s-triazine.  Very small amounts of the
didealkylated product, 2-chloro-4,6-diamino-s-triazine, were
detected (Adams et al., 1990).  Male Charles River rats fed simazine
were found to excrete the dealkylated 2-chloro-4-(ethylamino)-6-
amino s-triazine, as well the di-deethylated form, 2-chloro-4,6-
diamino-s-triazine, in their urine (Bradway and Moseman, 1982).
Hydroxy Simazine
(2-hydroxy-4,6-bis[ethylamino]-s-triazine)
                     
Mono-dealkylated Simazine, via deethlyation
(2-chloro-4-[ethylamino]-6-amino-s-triazine)
Di-dealkylated Simazine
(2-chloro-4,6-bis[amino]-s-triazine)
II. History of Use and Usage
A. History of Use and Usage:
Simazine is in the s-triazine herbicide family.  It was first registered
for use in 1957 by Ciba (now Norvartis), and in the mid-1990s
Ciba produced 80 to 90 percent of the technical product
(USEPA, 1994).  Simazine is a selective systemic pre-emergence
herbicide used in the United States (U.S.) for control of broadleaf
and grassy weeds primarily on corn (40%), citrus crops (22%),
alfalfa (11%) and grapes (7%) (Gianessi and Puffer, 1991).  It is
also used to control weeds on strawberries, peaches, cherries,
apples, pears, cranberries, certain nuts, olives, pineapples,
asparagus, sugar cane, tea and coffee.  Its non-cropland uses include
weed control in industrial areas (vacant lots), right-of-ways,
established Bermuda grass, in turf grass sod production, golf
fairways, and ornamental and tree nursery stock (Meister, 1998).
Simazine was used in lakes and ponds to control submerged weeds
and algae, and as an algaecide in swimming pools and hot tubs
until its registration for many aquatic uses were canceled in the
1980s and mid-1990s (see section III on ‘Regulatory Status, EPA’)
(Tomlin, 1994; USEPA, 1994).
B. Current Usage:
Simazine use on U.S. croplands during 1990-93 was estimated to
be 3.98 million pounds (lbs) of active ingredient (AI).  It is ranked
as the 20th most used herbicide in the U.S. (Gianessi and Anderson,
1995b).  In California, 1.1 million lbs was used in 1993, mostly to
control weeds on grapes, citrus, fruit and nut crops, and right-of-
ways (Bartowiak et al., 1995).  Use on New York State (NYS)
cropland during 1991-93 was estimated to be 88.9 thousand lbs of
AI, making simazine the 9th most used herbicide in NYS (Gianessi
and Anderson, 1995a).  The U.S. Environmental Protection Agency
(EPA) has estimated that 1.9 to 3.3 million lbs of simazine (AI) is
used per year for non-crop uses (Gianessi and Puffer, 1991).
III. Current Regulatory Status
A. Regulatory Status, EPA:
Simazine was classified as a Restricted Use Pesticide in 1984 by
the EPA because of concern for its potential to contaminate ground
water.  The restricted use classification was withdrawn in 1985,
but the EPA required labeling to include a ground water advisory,
and aquatic invertebrate toxicity statements.  Simazine is currently
classified as a General Use Pesticide.
In 1993, EPA conducted a risk assessment for simazine use as an
algaecide in swimming pools, hot tubs and whirlpools.  The risk
assessment concluded that water treated with simazine algaecides
represented an unacceptable cancer and non-cancer health risk to
children and adults.  Most registrants voluntarily canceled their
use of simazine algaecides effective April 15, 1994.  Registration
for remaining algaecide products which were not voluntarily
canceled were canceled through a Notice of Intent of Cancel
announced in the Federal Register on July 7, 1994 (USEPA, 1994).
In November of 1994, the EPA placed simazine, along with the
triazine herbicides atrazine and cyanazine, under Special Review.
The EPA initiated the Special Review because the agency
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concluded that these three s-triazines are possible human
carcinogens, and that exposure to these herbicides from consuming
treated foods, and / or contaminated water may pose a cancer risk.
Other concerns included potential risks to pesticide applicators
and mixers exposed to triazine pesticides (USEPA, 1994).  It is
expected that the EPA may make its preliminary decision regarding
the regulatory status of simazine in 1998, with a final decision
anticipated sometime in 1999 (BNA, 1997).
B. Drinking Water Standards and Health Advisories:
1. MCL:  The EPA has set Maximum Contaminant Level (MCL)
for simazine in drinking water at 0.004 mg/ L (USEPA, 1996).
The MCL is an enforceable limit for the maximum allowable
concentration of a chemical in public drinking water supplies.
2. HA: Health Advisory (HA)* levels for simazine in drinking
water are as follows:
       10 kg child:
•  One-day = 0.07 mg/L
•  Ten-day = 0.07 mg/L
•  Longer term 0.07 mg/L
      70 kg adult:
•  Longer term 0.07 mg/L
•  Lifetime = 0.002 mg/L
* The HAs are nonenforceable limits of the concentration of the
chemical in drinking water that is not expected to cause any adverse
non-carcinogenic health effects when consumed for no more that
the time period specified, with a margin of safety (USEPA, 1996).
C.  Food Residue Tolerances:
The Food and Drug Administration (FDA) and the U.S. Department
of Agriculture (USDA) are responsible for monitoring the levels
of simazine residues in domestic and imported foods and animal
feeds.  Because of new legislation set forth in the 1996 Food Quality
and Protection Act, the tolerances for simazine may be reset
according to the new guidelines.  Until the tolerances are reset,
current tolerance levels for simazine residues on raw agricultural
commodities and animal feed are: meat or fat portions of meat
from animals, 0.02 ppm (includes cattle, goats, horses, poultry
and hogs); eggs, 0.2 ppm; milk, 0.2 ppm; nuts, 0.1 to 0.25 ppm;
most stone, pom and citrus fruits and berries, 0.25 ppm; and animal
fodder and grasses, 0.25 to 15 ppm.  The combined tolerances for
residues of simazine and its metabolites 2-amino-4-chloro-6-
ethylamino-s-triazine and 2,4-diamino-6-chloro-s-triazine include:
0.2 ppm for bananas and 12 ppm for fish (USEPA, 1998).
IV.  Summary of Evidence of Overall
       Carcinogenicity
A. Human Studies (non-breast sites):
1. Case-Control Studies of Agricultural Workers:
Two case-control studies on the effect of triazine exposure on the
incidence of ovarian cancer have been conducted on female farm
workers in the Alessandria province of Northern Italy (Donna et
al., 1984; Donna et al., 1989).
Authors’ Note: We have provided a summary of the study by
Donna, et al. (1984) because it has been frequently cited as evidence
of a relationship between triazine herbicide exposure and the risk
of ovarian cancer.  However, the study only mentions that exposure
to “herbicides” were assessed by interview in this study, and there
is no mention of specific exposure to triazine herbicides anywhere
in the paper.  In a later study published by the same authors in
1989, it noted that in the first 1984 study interviewed subjects
frequently reported exposures to triazine herbicides, and that in
the 1970s there was a high use of triazines, especially atrazine,
and to a lesser extent, simazine, in the region of Italy where both
studies were conducted.
The 1984 study included 60 women with primary mesothelial
ovarian tumors and 127 hospital based cancer-controls with no
evidence of ovarian cancer that were matched by year of diagnosis,
age (+ 2.5 years) and residence.  Exposure was estimated by means
of a questionnaire as follows:  “definite exposure”- the subject or
next of kin described personal use of herbicides; “probable
exposure”- subject was a farmer after 1960 when use of herbicides
was extensive, or resided in areas with known herbicide usage; or
“no exposure”- denied personal use of herbicides.  An elevated,
but nonsignificant relative risk (RR) of 2.20 (95% Confidence
Interval [CI] 0.77-6.32) was observed in the women “ probably”
exposed to herbicides, while a significantly elevated RR of
4.38 (95% CI 1.90-10.07) was reported in the women with ovarian
cancer who were exposed to herbicides (combined “definite” and
“probable” exposure groups) as compared to the cancer case-
controls (Donna et al., 1984).
A subsequent study using more appropriate population-based
controls found that women “definitely” exposed to triazines had a
significantly elevated risk (RR = 2.7; 90% CI 1.0-6.0, p = 0.10)
for ovarian neoplasms compared to case-controls.  Those who were
“possibly” exposed to triazines had a lower RR of 1.8 (90% CI
0.9-3.5) (Donna et al., 1989). This study was based on 65 women
with diagnosed ovarian neoplasms, and 126 controls (two for each
case, matched for age + 5 years) who were recruited by random
selection from electoral rolls of surrounding towns.  Triazine
exposure was assessed by means of an interview-administered
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questionnaire.  Criteria for “definitely exposed” to triazines
included “subjects who were involved in the preparation or use of
triazine herbicides or who worked in corn cultivation with reported
use of herbicides” (Donna et al., 1989). It should be noted that this
study used 90% rather than the usual 95% CI in their statistical
analysis.
This study has been criticized because of the possibility of selection
bias (Minder, 1990).  This included interviewer bias, since the
interviewer may have been able to distinguish between the cases,
and the controls who were recruited much later.  Minder also
suggested that cases with higher-socioeconomic status may have
not sought treatment at the local hospital, but may have sought
treatment elsewhere in larger cities, resulting in an incomplete
recruitment of ovarian cancer cases.  The authors responded to the
concerns of Minder, stating that the interviewers were not aware
of the disease state of those interviewed, and their response also
discussed the completeness of recruitment of ovarian cancer cases
(Crosignani et al., 1990).
While other researchers have evaluated relationships between
agricultural triazine exposure in Midwestern states, none of these
studies specifically reported whether these populations were
exposed to simazine.  Since cyanazine and atrazine are the
predominant triazine herbicides used for weed control in the corn
belt of the Midwest, it is probable that the “triazine” exposures in
the Midwestern studies were predominantly to atrazine and
cyanazine.  For this reason, we have not included these triazine
studies in the simazine Critical Evaluation, but they are included
in the cyanazine and atrazine Critical Evaluations.
There is a paucity of studies on agricultural exposure to simazine
and cancer risk in fruit and nut growing states that use simazine
for weed control, such as California and Florida.  Because of the
large migrant population involved in the work force in these states,
including women and children, it presents the problem of assessing
health risks in an exposed mobile population.  Assessment of health
risks in migrant farm workers is also difficult because this
population does not always have access to or seek out adequate
health care, and they may be exposed to multiple pesticides over
the course of the year.
2. Cohort Mortality Studies of Manufacturing/Production
    Workers:
The mortality among males who worked at triazine herbicide
manufacturing plants was recently reported by Sathiakumar, et al.
(1996).  Women were not included in this study because of
insufficient numbers of subjects.  The study examined the
Standardized Mortality Ratios (SMRs = observed number of deaths
among cases, multiplied by 100, divided by the number expected
based on general population mortality rates) for all cancer deaths
and cancer deaths at specific sites. The study was based on reported
deaths during a 16 year period from 1960 to 1986 of 2,683 men
with definite or probable manufacturing exposure to triazine
herbicides, and 2,234 men with possible exposure to triazines.
No information was available on the types of triazines
manufactured at the plants. Most of the definitely / probably
exposed group (83%) began triazine-related work between 1960
through 1979, but only 12% were exposed for more than five years.
In the group possibly exposed to triazines, 30% had been exposed
to triazines for more than five years. The SMRs were not elevated
for overall cancer mortality in the probable / definitely triazine
exposed group (SMR = 85, 95% CI 46-142).  This may indicate a
“healthy worker effect” in this cohort.
In this same cohort, the risk of mortality from non-Hodgkin’s
lymphoma (NHL) was elevated in the triazine-exposed workers,
but it was not statistically significant (SMR = 385, 95% CI
79-1,124).  This was observed for a small number of cases (three
observed, 0.78 expected), and two of these NHL cases had worked
for less than one year in triazine-related jobs.  There was no other
cancer that had an elevated SMR in this cohort.  It was noted that
the insecticide DDT, other insecticides, and fungicides were
produced at the plants from 1952 to 1962, but information on
exposure of the workers to these chemicals, or previous
employment history of chemical exposures was not provided.  The
follow-up time may not have been sufficiently long in this cohort
to detect an increase in exposure-related cancer mortality, since
only 21% of the definite/probable group were followed for more
than 20 years (Sathiakumar et al., 1996).
3. Summary, Human Carcinogenicity (non-breast sites):
There is evidence of increased risk of ovarian cancer in women
agricultural workers exposed to triazine herbicides in one
population-based case control study conducted in Italy (Donna et
al., 1989).  A nonsignificant elevation in deaths from NHL was
observed in men employed and exposed to triazine herbicides that
may have included exposure to simazine (Sathiakumar et al., 1996).
B. Experimental Animal Studies (non-breast sites):
Chronic feeding studies have reported the induction of livers
tumors in male rats and pituitary tumors in female rats fed simazine
for up to two years, while in mice, there have been no reports of
an oncogenic effect of simazine.  It should be noted that the three
long-term studies describing simazine’s oncogenic potential in
rodents were only available in a summary or abstract form.
Complete details of the experimental design, tumor incidence,
tumor pathology, and other results were not always available.
Available results from the studies evaluating simazine’s oncogenic
potential in experimental animals are summarized below.
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1. Mice:
The “Drinking Water Criteria Document for Simazine” included a
summary of an unpublished mouse study that assessed the
oncogenicity of simazine (Dynamac, 1990). A summary of this
study (Hazelette and Green, 1988) was also cited in the EPA Special
Review Document on triazines (USEPA, 1994), and has been
included in the EPA Integrated Risk Information System’s (IRIS)
carcinogenic assessment for simazine (IRIS, 1997).  Male and
female Crl:CD1 (1CR) BR mice, 60 per sex per dose, were fed
diets containing 0, 40, 1000, and 4000 ppm simazine for 95 weeks.
There was no evidence of a carcinogenic effect of simazine in this
study.  However, the adequacy of the experimental design of this
study can not be determined due to the limited amount of
information available.  It was noted in the Dynamac (1990) and
IRIS database (1997) summaries stated that body weights were
significantly depressed (p<0.01) in the mid- and high-dose simazine
treatment groups compared to controls.
2. Rats:
An unpublished two-year cancer bioassay evaluating the
carcinogenic effect of simazine in Sprague-Dawley (SD) rats was
available in summary form in the “Drinking Water Criteria
Document for Simazine” (Dynamac, 1990), and in the EPA IRIS
database (1997). It has also been summarized and cited as an
unpublished Ciba-Giegy sponsored-study (McCormick and Arthur,
1988) in the EPA Special Review Document on simazine (USEPA,
1994).  Some of the results of this study have been published by in
a study authored by Stevens et al. (1994).
Sprague-Dawley (SD) rats, 50 of each sex per dose, were fed 0,
10, 100, and 1000 ppm simazine in the diet for two years.  In
contrast to the mouse cancer bioassay, there was a significant
increase in the incidence of hepatic carcinomas in the 100 ppm
dose group , and for combined liver adenoma / carcinoma in males
fed the 1,000 ppm simazine diet (Dynamac, 1990).  However,
commentary on this study in the EPA Special Review Document
on triazines stated that the incidences of the liver tumors fell within
the range for historical controls (USEPA, 1994).
Although there were statistically significant dose-related trends
for kidney tubule carcinomas, and for combined adenomas/
carcinomas in the male and female-simazine treated rats, the kidney
tumors were only detected in the 1000 ppm group.  There were no
significant differences in the incidence of kidney tumors in the
simazine treated animals in a pairwise comparison to concurrent
controls (USEPA, 1994).  In the same study, there was a significant
increase (p<0.01) in pituitary carcinomas in the female rats fed
diets containing 1000 ppm simazine (6/80; 8%) compared to
controls feed 0 ppm simazine (1/90; 1%). There were no treatment
related differences in the incidence of pituitary adenomas, though
the incidence was high in 0 ppm controls (73/90; 81%), and in all
simazine-treated groups of female rats (70%-80% incidence of
pituitary adenomas) (Stevens et al., 1994; USEPA, 1994).  (Note:
A significant increased incidence of mammary fibroadenomas and
adenocarcinomas where observed in the high-dose 1000 ppm
treatment group of this study; these results are discussed in Part
V., Section B.2 of this document).
Several studies evaluating the oncogenicity of long-term
administration of simazine in rodents found no evidence of tumors
in animals treated with simazine; however these studies were not
appropriate cancer bioassays because of inadequate number of
doses and insufficient number of animals per dose (Innes et al.,
1969), or an inappropriate use of a subcutaneous route of
administration for the test compound (IARC, 1980; Pliss and
Zabezhinsky, 1970).  Donna, et al.  (Donna et al., 1981) detected a
significantly higher (p<0.01) number of lymphomas in female
Swiss mice (3/24) injected with Fogard S, a formulation containing
atrazine and simazine, compared to saline injected controls
(0/50).  However, this study is of limited value for evaluating
carcinogenicity of simazine, because of the inappropriate route of
administration (intraperitoneal), limited duration of treatment
(13 doses over 39 days), inadequate follow-up time (up to 1 year),
and loss of animals due to disease (Donna et al., 1981).
3. Summary, Animal Experimental Studies
    (non-breast sites):
Simazine administration in experimental animal cancer bioassays
resulted in a significantly higher incidence of hepatic tumors in
male and female rats (McCormick and Arthur, 1988), and pituitary
tumors in female rats (Dymamac, 1990; Stevens et al., 1994;
USEPA, 1994) fed high-doses of simazine in two-year cancer
bioassays. Evidence of carcinogenicity was not observed in long-
term feeding studies conducted with simazine treated mice
(Hazelette and Green, 1988).
C. Current Carcinogenesis Classifications by Other
     Agencies:
1. IARC Classification:  Group 3, not classifiable as to its
carcinogenicity.  IARC concluded that there were not adequate
date available on the human or experimental animal carcinogenicity
of simazine (IARC, 1991).  Only studies that are available in the
open, peer-reviewed literature are included in IARC evaluations.
Hence, the unpublished oncogenesis studies of McCormick and
Arthur in rats (1988), and of Hazelette and Green (1988) in mice,
were not included in the IARC evaluation.
2. NTP Classification:  Not rated (USDHHS, 1998)
3. EPA Classification:  The EPA Special Review Document for
triazines lists simazine as a Class C Carcinogen (possible
carcinogen) (USEPA, 1994).
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V. Critical Evaluation of the Evidence for Breast
    Cancer Risk
A. Human Studies:
No case-control human epidemiology studies were located that
evaluated breast cancer incidence or mortality in women exposed
to simazine.
B. Experimental Animal Studies:
1. Mice:
There was no evidence of mammary carcinogenicity in mice fed
up to 1000 ppm simazine in a 95-week cancer bioassay sponsored
by Ciba Geigy (unpublished study, Hazelette and Green, 1988, as
cited in USEPA, 1994).  The adequacy of this study could not be
determined because details on the experimental design of this study
were not available.
2. Rats:
Mammary tumors have been observed in a chronic feeding study
of simazine in rats (McCormick and Arthur, 1988; Stevens et al.,
1994).  SD female rats were fed 0, 10, 100, and 1000 ppm simazine
in the diet for 104 weeks.  The incidence of fibroadenomas, and
the incidence of adenocarcinomas of the mammary gland were
significantly higher (p<0.01) in the only in high-dose 1000 ppm
simazine-treated group compared to control animals.  The incidence
of mammary fibroadenomas was 30% (27/90; number of animals
with tumor type/number of animals in dose-group) in the control
0 ppm group, 35% (28/90) in the 10 ppm group, 24% (19/80) in
the 100 ppm group, and 51% (41/80) in the 1000 ppm simazine-
treated group.  The incidence of mammary adenocarcinomas was
18% (16/90) in the 0 ppm control group, 16% (13/80) in the
10 ppm group, 25% (20/80) in the 100 ppm group, and 50%
(40/80) in the 1000 ppm simazine-treated group.  The incidences
of mammary fibroadenomas or adenocarcinomas in the 10 and
100 ppm simazine treated groups were within the range of reported
for historical controls (Stevens et al., 1994).  There were no
significant differences in the incidence of mammary adenomas in
the simazine-treated female rats compared to control rats in this
study (McCormick and Arthur, 1988 as cited in USEPA, 1994;
Stevens et al., 1994).
The mechanism by which simazine induces a higher rate of
mammary tumors in female rats fed high doses of simazine has
not been established.  One of the hypotheses for the induction for
mammary tumors in female SD rats is that s-triazines may induce
changes in the estrous cycle, the hormonally controlled
reproductive cycle, which may result in increased serum estrogen
levels (Eldridge et al., 1994; Stevens et al., 1994; Wetzel et al.,
1994).  This hypothesis could not be substantiated by other
investigators who found that ovarian hormone levels, including
estrogen and progesterone, were depressed in SD female rats
treated with the s-triazine, atrazine (Cooper et al., 1996).  Others
have hypothesized that s-triazines induce premature reproductive
aging in the SD rat (Chapin et al., 1996) and cause mammary
tumors to appear earlier in the female SD rat which has a high
spontaneous rate of mammary tumor development.   Since most
of the studies evaluating these hypotheses have been done on
atrazine-treated rats, the results of these studies are discussed in
the Critical Evaluation on atrazine.
Few studies have evaluated changes in the estrous cycle or early
hormonal changes in simazine treated rats.  One study reported
that rats fed high doses of simazine for two years have changes in
serum hormone levels compared to controls (Stevens et al., 1994).
Serum estradiol levels were significantly depressed (p<0.05) in
aging SD rats that had been fed 1000 ppm simazine for 24 months
(2 + 1 ng estradiol /ml) compared to animals receiving 0 ppm
simazine (12 + 6 ng estradiol/ml).  Estradiol levels were also lower,
but were not statistically significant, in the rats fed the diets
containing 10 ppm (8 + 4 ng estradiol/ml) and 100 ppm (5 + 2 ng
estradiol/ml) simazine compared to controls.  Serum progesterone
levels were also significantly depressed (p<0.05) in SD rats fed
1000 ppm simazine diet (11 + 9 ng/ml) compared to controls
(39 + 26 ng/ml).  Serum prolactin levels were significantly elevated
(p < 0.01) in the 1000 ppm dose group (204 + 147 ng/ml) compared
to 0 ppm controls (29 + 18 ng/ml) (Stevens et al., 1994).
Whether these hormonal changes contributed to the higher
incidence of mammary tumors in the SD rats fed the higher doses
of simazine is not known.  There is some evidence for a role of
prolactin in the growth of mammary tumors in rodents.  Early
studies by Pearson et al. (1969) demonstrated that injections of
prolactin supported the growth of DMBA-induced mammary
tumors in ovariectomized / adrenalectomized female rats, and later
studies by Koseki et al. (1987) found that prolactin administration
increased the levels of estrogen receptor and progesterone receptor
in the normal mammary gland, but not in transplanted mammary
tumors.  The role of prolactin in human breast cancer is less clear,
since studies in higher level primates have not shown a role for
prolactin in mammary gland development, nor has treatment of
women with breast cancer with prolactin-lowering drugs been
effective (Kleinberg, 1987).
C. Other Relevant Information on Breast Cancer Risk
1. Evidence of Estrogenicity:
Based on studies reported by several laboratories, simazine is not
estrogenic in either in vitro or in vivo assays.  In the E-Screen
assay for estrogenicity, simazine did not stimulate cell proliferation
in an estrogen-dependent MCF-7 human breast tumor cell line
(Soto et al., 1995).  A lack of a proliferative response in simazine
treated estrogen-dependent MCF-7 breast tumor cells, and PL3
yeast cells was also observed by Connor et al. (1996).  No
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estrogenic response was demonstrated in simazine-treated HeLa
cells transfected with a Gal4-human estrogen receptor chimeric
construct and a luciferase reporter gene (Balaguer et al., 1996).
Tran, et al. (1996) have reported that simazine was not estrogenic
when tested using yeast transfected with the human estrogen
receptor (hER) and an estrogen-sensitive reporter.  Competition
binding assays demonstrated that simazine displaced radiolabeled
estradiol from the recombinant hER, suggesting that this herbicide
may have some anti-estrogenic activity (Tran et al., 1996).
Several in vivo tests have confirmed the lack of simazine’s
estrogenicity in female SD rats.  Ovariectomized rats gavaged with
100 or 300 mg/kg bwt simazine for three days failed to show a
significant increase in estrogen-dependent uterine weight gain
compared to animals treated with vehicle (Tennant et al., 1994).
A lack of an estrogenic uterotropic response in immature uteri
was also observed in simazine-treated rats by Connor, et al. (1996).
Tennant et al,, (1994), in another experiment found that the
administration of 50, 100, or 300 mg simazine /kg bwt for two
days significantly depressed (p<0.05) estradiol-stimulated tritiated
thymidine incorporation into uterine DNA of ovariectomized
female SD rats.  Lower doses of 1 or 10 mg simazine per kg bwt
did not suppress estrogen-stimulated thymidine uptake (Tennant
et al., 1994). These tests would suggest that simazine is not
estrogenic.  The suppression of estradiol-stimulated thymidine
incorporation in the uteri of ovariectomized rats suggests that
simazine may have some weak anti-estrogenic activity.
2. Reproductive Toxicity:
Mallard ducks exposed to two or 20 ppm simazine prior to the
onset of egg laying, and throughout the egg production cycle,
displayed no signs of reproductive impairment (Fink, 1975).  The
reproductive and developmental toxicity of pesticide/fertilizer
mixture that was based on levels of pesticides found in California
groundwater was assessed in SD rats, and Swiss CD-1 mice
(Heindel et al., 1994).  This “California” pesticide mixture included
two other s-triazines, atrazine and cyanazine, among its
components.  Pesticide mixtures were administered in the drinking
water at 1X (0.061 mg simazine /kg bwt/day), 10X and 100X the
median concentration reported in California groundwater.  These
concentrations were well below the Maximum Tolerated Dose
(MTD), since these levels were designed to assess health effects
of concentrations of pesticides that may actually occur in
groundwater.  The National Toxicology’s Reproductive Assessment
by Continuous Breeding protocol was used to evaluate reproductive
endpoints, and included measurements of fertility, reproductive
performance in the F0 and F1 generations, and measures of
spermatogenesis.  There were no adverse effects reported at any
dose of the California pesticide mixture on any reproductive
endpoints.  There were no treatment-related effects on
development.  No deaths or dose-related clinical signs of maternal
toxicity were reported in treated animals.  There were no external,
craniofacial, skeletal, viseral or other morphological malformations
in pups born to dams treated with drinking water containing
simazine during gestation (Heindel et al., 1994).
3. Formation of Co-Carcinogens:
Janzoski, et al (1980) have hypothesized that simazine, which
contains a secondary amine group, could react with nitrous oxide
in the atmosphere to form nitrosamines.  Nitrosomines are
carcinogens associated with an increase risk of stomach cancer.
Subsequent studies with in vitro  systems indicated that simazine
is capable of undergoing nitrosation by nitrous oxide (Janzowski
et al., 1980).  However, the extent to which simazine reacts with
nitrous oxide to form nitrosomine compounds, and whether such
compounds contaminate water supplies or are present in soil has
not been determined. Whether nitrosomines can act as co-
carcinogens and influence the incidence of non-stomach cancers,
such as breast cancer, has not been determined.
4. Mutagenicity:
While the genotoxic properties of simazine have not been studied
as widely other s-triazines, the weight of evidence suggests
simazine is not genotoxic.  The Special Review Document on
triazines (USEPA, 1994) cites an unpublished mutagenicity study
on simazine using the Salmonella assay, which was negative
(Lasinski et al., 1987). Other studies have evaluated the genotoxic
potential of simazine in multiple test systems.  The mutagenicity
of simazine was tested in bacteria (S. typhimurium ) and yeast
(S. cervevisiae) assays with liver microsome activation, plant
activation and no activation (Plewa et al., 1984).  Simazine tested
negative in all S. typhimurium genotoxic  assays, and only tested
positive in a plant activated (maize 1S fraction) S. cervevisiae
assay.  Simazine does not appear to be genotoxic in mammalian in
vitro systems.  Simazine tested negative in lymphocyte sister-
chromatid exchange tests, and in alkaline elution assay with rat-
hepatocytes, v79 cells, and human lymphocytes (Dunkelberg et
al., 1994).  Simazine was also found to be non-genotoxic in the
chromosome aberration test in human fibroblasts, and did not
increase sister chromatid exchange frequency in Chinese Hamster
Ovary (CHO) cells (Dunkelberg et al., 1994).  Simazine did not
demonstrate whole cell clastogenicity in CHO cells exposed two
clastogens, adriamycin and araj-C (Biradar and Raybrun, 1995b).
The same authors also did not find evidence of chromosomal
breakage in CHO cells exposed to simazine at levels similar to
those found in public water supplies (Biradar and Rayburn, 1995a).
In contrast, simazine tested as Princep 80W (80% simazine) was
shown to increase the rate of dominant lethals in Drosophila
melanogaster.  Simazine increased the risk of x-linked lethals, but
did not affect the loss of the Y chromosome or the sex chromosome
disfunction (Murnik and Nash, 1977).
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VI. Other Relevant Information
A. Environmental Fate:
1. Soil:
The half-life of simazine in soil is variable, and has been reported
to be in the range of as little as 12 days to as long as 2 years. The
persistency of simazine is dependent on soil type, organic matter
content, pH, temperature, soil microbes and moisture content.
Studies that have evaluated the half-life of simazine under different
soil conditions are summarized below.
Chen et al. (1983) reported that the half-life of simazine was
influenced by climatic conditions in Taiwan.  The half-life for
simazine was 18 days in the summer months in when it is hot and
wet, compared to 24 days in the cooler, drier winter season.  These
authors also presented a table which summarized the half-lives of
simazine in soils from Canada, Central Europe and Taiwan.  Soils
from Saskatchewan and Alberta, Canada had the longest half-life
ranging from 88 to 101 days.  Shorter half-lives were reported for
central European countries (Germany, Italy, Holland) that ranged
from 54 to 30 days, while Taiwan had the shortest half-life for
simazine in soil, in the range of 14 to 18 days (Chen et al., 1983).
The organic carbon content has also been found to influence the
half-life of simazine in soil in field studies.  In  acidic soil (pH 5.4-
5.5) from New Zealand, the half-life of simazine was 25 days when
the organic carbon level was 4.6%, and the half-life increased to
32 days in soil with organic carbon levels of 9.4%.  The authors
also provided some information that suggested that higher
application rates of simazine increased the persistency of this
herbicide in soils (Rahman and Holland, 1985).  One of the shortest
half-lives published was reported in soil obtained from a Spanish
citrus orchard.  The half-life of simazine was only 12 days in sandy
clay with a pH of 7.4 to 7.5 (Redondo, 1997).
Several reference texts and reviews have also reported half-lives
for simazine.  Ahrens (WSSA, 1994) has reported that the half-
life of simazine in sandy loam under aerobic conditions was
91 days, while the half-life was 70 to 77 days under anaerobic
conditions.  In an EPA summary, simazine’s half-life under
controlled aerobic conditions was 110 days, while under anaerobic
conditions, the half-life was approximately two years (USEPA,
1994).  A recent review of the transport of pesticides in field soils
reported that the average half-life of simazine from ten field
experiments was 60 days, but information was not provided on
the field conditions of these studies (Flury, 1996).  The “Drinking
Water Criteria Document for Simazine” estimated the half-life of
simazine to be between four and six months in soil, and 50 to
70 days in water (Dynamac, 1990).
Many studies have evaluated the persistence of simazine in
agricultural soil used for crop weed control.  However, simazine
was also applied at high rates to control weeds in irrigation ditches.
Smith et al. (1975) determined the persistence of simazine applied
at 22.4 kg/ha in irrigation ditches in September of 1970.  Soil
samples from ditch sides, bottoms, and water samples from the
ditch and water basin, were taken twice a year over the next three
years.  After initial application in September, 1970, simazine
residues were 12.5 ppm in the ditch bottom and 4.7 ppm in the
ditch side, based on a core soil sample taken at 0-15 cm.  Samples
taken in the upper 7.5 cm had consistently higher levels of simazine
residues than samples taken from greater depths. Simazine was
persistent in the upper layers of the ditch soil, with the levels only
slightly decreasing over three years. Simazine residues in the 0 to
7.5 cm layer from the ditch side were 5.5 ppm in June of
1971 compared to 3.5 ppm in September of 1973.  Simazine
residues in deeper layers were of less magnitude, usually less than
1 ppm in samples taken at a depth of 7.5 to 90 cm in the ditch
bottom or sides during the three year sampling period. Simazine
was still detected in water samples taken from the ditch
(42 + 35 ppb) and basin (5 + 5 ppb) after the sixth irrigation in
June of 1973.  Simazine residues were not detected in water samples
taken after the tenth irrigation in September of 1973.  This study
indicates that simazine residues can persist in irrigation ditches
after application, and are detected in the upper levels of soil from
irrigation ditches, and from basin water samples 2 1/2 to 3 years
after application.
2. Surface water:
While simazine has been detected in surface waters from
Midwestern states, Florida, and several Northeastern states, nearly
all of the maximum levels reported are below the MCL for
simazine.
The EPA (1994) has compiled summaries of surface water
monitoring studies for simazine and other s-triazines in the
Midwestern corn belt.  These summaries were largely based on
studies conducted in the mid-1980s to the early 1990s.  While the
triazine herbicides atrazine, cyanazine, and simazine were
frequently detected in the surface waters of the corn belt, simazine
was detected less often, and at lower concentrations.  For instance,
the median concentration of the maximum levels of simazine
detected ranged from 0.07 to 0.78 µg per L, compared to 0.83 to
22 µg per L for atrazine, and 0.45 to 4.4 µg per L for cyanazine.
This may be due to the lower amounts of simazine, compared to
the other triazines, used in controlling weeds on corn fields in the
Midwest (USEPA, 1994).
The 1994 EPA report noted that there was little information
available on surface waters which drained from areas where
simazine was used on non-corn crops, such as orchards or nut
trees (USEPA, 1994).  One recent study has been published on
residues of simazine, and other pesticides, in the canals of southern
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Florida (Miles and Pfeuffer, 1997). In this region, the primary use
of simazine is in citrus orchards.  There were 744 pesticide
detections, 74 of these detections were simazine.  The highest
concentration reported was 2.5 µg per L which is below the MCL
of 4 µg per L (mean and median values were not available) (Miles
and Pfeuffer, 1997).
There is some information available on simazine levels in surface
waters of the Northeastern U.S.  The U.S. Geological Survey
determined the concentration of pesticides from 46 sites on
42 streams and rivers that fed into the Hudson River Basin of
western New York State.  Simazine was detected in 28% of the
sampled sites, with median concentrations of 0.13 µg per L, and a
maximum concentration of 0.55 µg per L (Wall and Phillips, 1997).
None of the samples exceeded the MCL for simazine.  In water
samples obtained from several Vermont streams during 1992 and
1993, 11.8% of the samples (n=17) from the Hungerford Brook
had detectable levels of simazine.  The mean concentration of
simazine was 0.15 µg per L with a maximum concentration of
0.2 µg per L (Gruessner and Watzin, 1995).
3. Groundwater:
Simazine was one of the most commonly detected pesticides in
well water in the EPA National Pesticide Survey.  The survey
estimated that 0.2% of all rural domestic wells (25,000 wells) and
1.1 % of community supply wells (1,080 in number) would have
detectable levels of (at least 0.38 µg/L) of simazine in the U.S.
(USEPA, 1990).  Simazine was the most frequently reported
pesticide in the 1995 California Well Water survey (Bartowiak et
al., 1995).  In California, current uses of simazine include weed
control on grapes, citrus, other fruits, nuts and on right-of-ways.
Of the 2,202 wells sampled, 142 wells had verified detections of
simazine.  Levels ranged from 0.05 to 1.0 µg per L; none of the
detections exceeded the MCL of 4.0 µg of simazine per L.  These
levels are lower than those reported in California wells in early
1983 (0.5 to 3.5 µg per L) by the California Dept. of Food and
Agriculture as cited by Ritter (1990).
The U.S. Geological Survey, as a part of the National Water-Quality
Assessment Program (NAQUA), determined the levels of
pesticides in shallow ground water during 1993-95 in 20 major
hydrologic basins in the U.S with different land uses (Kolpin et
al., 1998).  While very low levels of triazine residues were widely
detected, samples rarely exceeded the MCL set by the  EPA for
drinking water.  The three pesticide residues detected most
frequently (percentage of sites with positive detections) were
atrazine (38.2%), deethylatrazine (34.2%) and simazine (18%).
However, there were no simazine samples which exceeded the
MCL of 4.0 µg/L.  The maximum concentration detected for
simazine in groundwater was 1.30 µg/L.  The land use settings
that reported detections of simazine in at least 10% of the sampled
sites included:  corn and alfalfa (28.0 %), corn (26.2 %), wheat
(43.0%), wheat and small grains (11 %), orchard/vineyard
(31.7 %), and urban settings (10 %).  The only detections that are
inconsistent with simazine’s uses is the detection in groundwater
where wheat crops were grown.  Simazine is not usually used as a
herbicide on wheat crops, though it is used on alfalfa.  The authors
suggested that the detections of simazine in groundwater associated
with wheat growing sites may be due to the permeable soils and
intensive irrigation associated with the wheat crop areas sampled.
B. Dietary Cancer Risk:
Contamination of water supplies with simazine and its breakdown
products is the most often cited route of exposure to this herbicide.
However, in the EPA’s Special Review Document on triazines
(USEPA, 1994), concern was expressed regarding dietary cancer
risk of simazine and simazine breakdown products.  As has been
stated previously, the EPA has set tolerance levels for the maximum
levels of simazine and its breakdown products in raw agricultural
products and animal feed (USEPA,1998).  In the Special Review
Document on triazines, calculations of cancer risk posed by
ingestion of residues of simazine or its breakdown products in
food were calculated (see Table 2 in USEPA, 1994).  These upper
bound cancer risk estimates were calculated from anticipated
residues of commodities known to be treated with simazine, the
percent of the crop treated with simazine, and the estimated
exposure in mg/kg/day to simazine. Simazine’s total estimated
dietary cancer risk from all commodities was calculated to be
1.1 x 10-5.
VII.  Summary and Recommendation for
         Breast Cancer Risk Classification
Based on the lack of available studies that have evaluated the
incidence of breast cancer in simazine-exposed populations, limited
evidence of mammary carcinogenicity in experimental animal
studies, and limited evidence of mechanisms by which simazine
can affect breast cancer risk, we conclude there is inadequate
evidence to rate simazine as a human breast carcinogen, and
recommend that it be classified in Group 3, unclassifiable as to
its breast cancer risk  (see Appendix B for the BCERF Breast
Cancer Risk Classification System).  This evidence is summarized
below.
•  Human Studies: Case-control studies have not been published
that have evaluated the effect of exposure to simazine on the risk
of developing breast cancer in women.  Therefore, we could not
adequately assess whether or not simazine directly causes breast
cancer in humans.
•  Animal Experimental Studies:  There is limited evidence that
simazine is a mammary carcinogen in experimental animals.  This
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evidence is based on one animal study which reported a significant
elevation of fibroadenomas and adenocarinomas only in the female
SD rats receiving the highest dose of simazine (1000 ppm).  A
significant increase in the incidence of these mammary tumors
was not reported in the 10 and 100 ppm simazine treated groups
compared to 0 ppm controls (McCormick and Arthur, 1988;
Stevens et al., 1994).
•  Related Mechanisms: There is no compelling evidence to show
that simazine is a co-carcinogen, tumor promoter, or increases
normal or neoplastic cell proliferation rate in human breast cells
or tissue.  There is no evidence that simazine is estrogenic (Connor
et al., 1996; Soto et al., 1995; Tennant et al., 1994; Tennant et al.,
1994).  The mechanism by which simazine induces mammary
tumors when fed at high levels to SD female rats has not been
established, though it has been suggested that s-triazine compounds
may alter hormonal profiles in the SD female rat that may influence
the development of mammary tumors in this strain (Chapin et al.,
1996; Eldridge et al., 1994; Stevens et al., 1994; Wetzel et al.,
1994).
Author’s Comment:  While there is inadequate evidence to rate
simazine as a human mammary carcinogen, this compound does
have a high usage in the U.S., especially on fruit crops, including
citrus, grapes, and apples. Simazine is commercially available as
a pre-mix with atrazine, another s-triazine for which there is
sufficient evidence of mammary tumor induction in experimental
animals.  It is likely that these two compounds are metabolized
similarly, and may have commonalties with regard to mode of
action to induce mammary cancer in animal models.  Therefore,
there may be additive effects in regard to their exposure when
used simultaneously in weed control.  Individuals that are involved
in the manufacturing of s-triazines; handle, mix or apply simazine-
containing products; work in fields or orchards treated with
simazine; or consume water from highly contaminated rural wells
that are near pesticide mixing operations, have the highest likely
hood of being exposed to simazine and its breakdown-products.
VIII. Research Gaps and Recommendations for
        Further Research
•  Case-control human epidemiological studies are needed to
determine if there is a higher incidence of cancers of the breast or
ovaries in females exposed occupationally to simazine and atrazine.
This includes women employed in manufacturing facilities, as
pesticide applicators, and other agricultural workers exposed to
these triazine pesticides.  These studies are needed to confirm or
negate the original findings of Donna, et al., suggesting that these
triazines are ovarian carcinogens and to determine if either triazine
poses a risk for cancer in other hormonally-sensitive tissues such
as the breast.  If a relationship is found between simazine exposure
and ovarian/breast cancer risk in occupationally exposed
opulations, then studies would need to be extended to other
populations with exposures to simazine.  This would include those
who have lived on orchards or farms that have used simazine,
those who have handled or laundered clothing contaminated with
simazine, and those who have lived in areas with historical
problems with simazine-contaminated drinking water supplies.
•  Studies are needed to further characterize the nature of and
persistency of simazine transformation products in soils and foods,
and whether any of these breakdown products have the potential
to induce adverse health effects.
•  Further studies are needed to determine the mechanism by which
simazine-induces mammary tumors in female SD rats and the
relevance of these mechanisms to humans.
•  Studies are needed to develop biomarkers for simazine, its
breakdown products, and  metabolites in humans, in order to more
accurately assess exposures in human populations.
IX. Summary of Studies Currently Being
      Conducted:
The following studies were abstracted from the CRISP database,
which lists studies funded by federal agencies (i.e. NIH, EPA,
USDA), or where obtained through personal communications with
the principal investigators.
Agricultural Health Study; joint intramural research, NCI and
NIEHS
Dr. Michael Alavanja, Project Officer, NCI
(personal communication with Dr. Alavanja)
This 10-year prospective study, which is its fourth year, will follow
90,000 farmers,  commercial pesticide applicators, and spouses of
farmers and applicators in Iowa and North Carolina.  The survey
will document pesticide usage by questionnaire, and in a subset of
the population, actual pesticide exposures will be measured in the
urine and blood using validated biomarkers.  Information will also
be gathered on home use of pesticides, as well as agricultural uses
of pesticides.  This study is unique, since it will include one of the
largest cohorts of female pesticide applicators ever followed, as
well as including the female spouses of farmers and pesticide
applicators. Approximately 58,000 men and 32,000 women are
enrolled in this study.  Case-control breast cancer, and ovarian
cancer studies as well as other case-control studies of cancer are
planned.
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Biomarkers of Exposure to Hazardous Substances
Dr. Bruce D. Hammock, University of California at Davis
(adapted from 1997 CRISP database)
This study will include developing rapid immunochemical assays
to detect pesticides, and environmental breakdown products of
pesticides.  Triazines are one group of pesticides that have been
targeted for development and validation of these immunoassays.
The researchers have also proposed to develop assays to assess
human exposure to triazines by measuring triazine metabolites,
including triazine mercapturate.
Studies of Manufacturing Workers Exposed to Triazines
Ciba-Giegy Corp (personal communication; letter from Mr.
Kerry Miller, Regional State Gov. Relations Manager for
Ciba, dated October 21, 1996).
Epidemiological studies are ongoing to monitor workers exposed
to simazine at production facilities. However, since entrance of
women into these facilities is relatively recent, it is possible that
this small female cohort may not have been monitored for a
sufficient period of time to date to warrant valid conclusions.
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XI.  Appendix A.  Common Abbreviations,
Acronyms and Symbols
AI Active Ingredient
BCERF Program on Breast Cancer and Environmental
Risk Factors in New York State, based the
Cornell’s Center for the Environment, Institute
of Comparative and Environmental Toxicology
bwt body weight
C carbon
CAS Chemical Abstract Service
CfE Cornell University’s Center for the Environment
CI Confidence Interval
Cl chlorine
cm centimeter
CRISP Computer Retrieval of Information on Scientific
Projects; database of scientific intra- and 
extramural projects supported by the Dept. of
Health and Human Services (i.e., NIH, EPA,
USDA)
DNA deoxyribonucleic acid
ER estrogen receptor
FDA Food and Drug Administration
H hydrogen
ha hectare, equivalent to 2.71 acres or 10,000
square meters
HA The health advisories are nonenforceable limits
of the concentration of the chemical in the drink
ing water that is not expected to cause any 
adverse non-carcinogenic health effects when
consumed for no more than the time period
specified, with a margin of safety
hER human estrogen receptor
IARC International Agency for Research on Cancer,
headquartered in Lyon, France
ICET Institute for Comparative and Environmental
Toxicology
i.p. interperitoneal
IRIS Integrated Risk Information System; EPA risk
assessment database
kg kilogram
L liter
µg microgram
mg milligram
MCF-7 Cells derived from human breast tumor 
developed by the Michigan Cancer Foundation
MCL Maximum Contaminant Level; enforceable limit
set by the EPA which sets the maximum level
of a contaminate in a public drinking water 
supply
ml milliliter
n number of subjects/animals in the group
NAQUA National Water-Quality Assessment Program
ng nanograms; one billionth of a gram
N nitrogen
NHL non-Hodgkin’s lymphoma
NCI National Cancer Institute
NIEHS National Institute of Environmental Health 
Sciences
NIH National Institutes of Health
NTIS National Technical Information Service; 
repository for federal agency technical reports
NTP National Toxicology Program
NY New York
NYS New York State
OR Odds Ratio
ppm parts per million
ppb parts per billion
RR Relative Risk
SD Sprague-Dawley; rat strain
SMR Standardized Mortality Ratio; SMR= the ratio
of “observed” to “expected” deaths,multiplied
by 100.
TWA Time-weighted average
U.S. United States
USDA United States Department of Agriculture
USDHHS United States Department of Health and Human
Services
USEPA United States Environmental Protection Agency
WHO World Health Organization
wt weight
Symbols:
α alpha
β beta
γ gamma
µg microgram
< less than
> greater than
% percent
p p value
+ plus or minus
= equal
® registered trademark
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XII.  Appendix B. BCERF Critical Evaluations of Breast Cancer Risk
This includes an overview of the Critical Evaluations and explanation of the BCERF Breast Cancer Risk Classification Scheme (revised
10/98 sms).
The Process:
Starting Point - Existing Critical Evaluations on Evidence of Carcinogenicity
IARC  Monographs (International Agency for Research on Cancer)
NTP ARC (National Toxicology Program, Annual Report on Carcinogens)
ATDSR (Agency for Toxic Disease Substance Registry)
Conduct Literature Searches using databases to obtain historical and the most recent information; i.e. Toxline, Medline, Biosis, Cancerlit
-Peer-reviewed scientific literature-available through Cornell libraries and
interlibrary loans.
-Technical Reports-NTIS-National Technical Information Service
-TOXNET databases—USEPA’s IRIS database source of oncogenicity and regulatory status information
-Gray literature—Studies submitted to U.S. Environmental Protection Agency (EPA) that are not published—i.e. industry
generated oncogenicity studies
-Some abstracts of cancer bioassays are on line (IRIS database)
-Request reports from industry
-Request reports from EPA through Freedom of Information Act
The Critical Evaluation includes some general background information, including: chemical name, chemical formula, Chemical Abstract
Subject Registry no. (CAS #), chemical structure, trade name(s), trade names of mixtures, metabolites/degradation products, history of
use, and current regulatory status.
Evidence of cancer in other (non-breast) organ systems is provided in synopsis form with some critical commentary, along with the
current overall carcinogenicity classification by international (IARC) and U.S. Federal Agencies (NTP, USEPA).
Human epidemiological studies, animal studies, and other relevant studies on possible mechanisms of carcinogenesis are critically
evaluated for evidence of exposure to agent and breast cancer risk based on “strength of evidence” approach, according to a modification
of IARC criteria as listed in the IARC Preamble.  (See attached sheets for a more detailed explanation of the BCERF Cancer Risk
classification scheme)
The emphasis of the document is a critical evaluation of the evidence for breast cancer risk, classification of the agent’s breast cancer
risk, identification of research gaps, and recommendations for future studies.  A section is devoted to brief summaries of new research
studies that are in progress.  A bibliography with all cited literature is included in each critical evaluation.  Major international, federal and
state agencies will be provided with copies of our report.
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General Outline of BCERF Critical Evaluations-revised 10/98 sms
I. Chemical Information
A. Common Name
B. Chemical Name(s)
C. Chemical Formula(s)
D. CAS # (Chemical Abstract Service Number)
E. Chemical Structure
F. Trade Name(s)
G. Trade Names of Mixtures
H. Major Metabolite(s)/Breakdown Products
II. History of Use, Usage
A. History of Usage and Uses
B. Current Usage (when applicable)
III. Current Regulatory Status
A. Current Regulatory Status, EPA
B. Drinking Water Standards and Health Advisories
C. Food Residue Tolerances and Action Levels (when applicable)
D. Workplace Regulations (when applicable)
IV. Summary of Evidence of Overall Carcinogenicity (non-breast sites)
A. Human Studies
B. Experimental Animal Studies
C. Current Classification of Carcinogenicity by other Agencies
1. IARC (International Agency for Research on Cancer)
2. NTP (National Toxicology Program)
3. USEPA (Environmental Protection Agency)
V. Critical Evaluation of the Scientific Evidence for Breast Cancer Risk
A. Humans Studies
1. Case-Studies
2. Human Epidemiological Cohort Studies
3. Human Epidemiological Case-Control Studies
4. When available will summarize information on detection/accumulation in human tissues / and validation of biomarkers
B. Experimental Animal Studies
C. Other Relevant Information, including mechanisms by which exposure may affect breast cancer risk (examples:  co-
carcinogenicity, tumor promotion estrogenicity, endocrine disruption, reproductive toxicology, mutagenicity, cell proliferation,
oncogene/tumor suppressor gene expression, immune function, etc.)
VI. Other Relevant Information
A. Specific for the pesticide; (i.e. may include information on environmental fate, potential for human exposure)
VII. Summary, Conclusions, Recommendation for Breast Cancer Risk Classification
VIII.  Identification of Research Gaps, and Other Recommendations
IX. Brief Summaries of New Human Studies Currently Being Conducted
X. Bibliography
XI. Appendix A. Common Abbreviations, Acronyms and Symbols
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BCERF Breast Cancer Risk Classification Scheme-
(adapted from the IARC Preamble by S.M. Snedeker; revised 12/97, 10/98 sms)
Group 1:  Human breast carcinogen; sufficient evidence  of
carcinogenicity to humans is necessary.  Sufficient evidence  is
considered to be evidence that a causal relationship has been
established between exposure to the agent and human breast cancer.
Group 2A:  Probable breast carcinogen; this category generally
includes agents for which there is 1) limited evidence  of breast
carcinogenicity in humans and sufficient evidence  of mammary
carcinogenicity in experimental animals.  The classification may
also be used when there is 2) limited evidence  of breast
carcinogenicity in humans and strong supporting evidence from
other relevant data, or when there is 3) sufficient evidence  of
mammary carcinogenicity in experimental animals and strong
supporting evidence from other relevant data.
Group 2B:  Possible breast carcinogen; this category generally
includes agents for which there is 1) limited evidence  in humans
in the absence of sufficient evidence  in experimental animals; 2)
inadequate evidence  of carcinogenicity in humans or when human
data is nonexistent but there is sufficient evidence of carcinogenicity
in experimental animals, 3) inadequate evidence  or no data in
humans but with limited evidence  of carcinogenicity in
experimental animals together with strong supporting evidence
from other relevant data.
Group 2C:  Potential to affect breast cancer risk; this category
includes agents for which there is inadequate or nonexistent human
and animal data, but there is supporting evidence from other
relevant data that identifies a mechanism by which the agent may
affect breast cancer risk.  Examples are, but are not limited to:
evidence of agent’s estrogenicity, disruption of estrogen
metabolism resulting in potential to affect exposure to estrogen;
evidence of breast  tumor promotion, progression or co-
carcinogenicity; increased expression of proto-oncogenes or
oncogenes; evidence of inactivation of tumor suppressor gene
associated with breast cancer; evidence of adverse effect on
immune function; or evidence of a structural similarity to a known
breast carcinogen (structure-activity relationship).
Group 3: Not classifiable as to its breast carcinogenicity to humans.
Agents are placed in this category when they do not fall into any
other group.
Group 4: Probably not a breast carcinogen in humans:  This
category is used for agents for which there is evidence suggesting
a lack of breast carcinogenicity in human studies and in animal
studies, together with a lack of related evidence which may predict
breast cancer risk. The absence of studies does not constitute
evidence for a lack of breast carcinogenicity.
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BCERF Breast Cancer Risk Classification Scheme,
continued
Brief Definitions of Sufficient, Limited, and Inadequate Evidence:
(adapted from the IARC Preamble by S.M. Snedeker)
Human Studies
Sufficient evidence of carcinogenicity in humans:  Must have
established evidence between exposure to the agent and human
breast cancer.  Case-reports are given the least weight in considering
carcinogenicity data in humans—they are suggestive of a
relationship, but by themselves cannot demonstrate causality.
Consistent, case-control studies which have controlled for
confounding factors and have found high relative risks of
developing breast cancer in relation to an identified exposure are
given the most weight in determining a causal relationship.
Limited evidence of breast carcinogenicity in humans:  A
positive association has been observed between exposure to the
agent and breast cancer, but chance, bias or confounding factors
could not be ruled out.
Inadequate evidence of breast carcinogenicity in humans:  The
available studies are of insufficient quality, consistency or statistical
power to permit a conclusion regarding the presence or absence of
a causal association.
Experimental Animal Studies:
Sufficient evidence of breast carcinogenicity in animals:
Evidence of malignant tumors or combination of benign and
malignant tumors in (a) two or more species of animals, (b) or two
or more independent studies in one species carried out at different
times or in different laboratories or under different protocols.
Limited evidence of breast carcinogenicity in animals: The
studies suggest a carcinogenic effect, but are limited for making a
definitive evaluation because: (a) the evidence of carcinogenicity
is restricted to a single experiment; (b) there are unresolved
questions regarding the adequacy of the design, conduct or
interpretation of the study; or (c) the agent increases the incidence
of only benign neoplasms of lesions of uncertain neoplastic
potential, or of certain neoplasms which may occur spontaneously
in high incidences in certain strains of animals.
Inadequate evidence of breast carcinogenicity in animals:  The
studies cannot be interpreted as showing either the presence or
absence of a carcinogenic effect because of major qualitative or
quantitative limitations.
